Chiesi agrees to acquire KalVista for $1.9B. Deal expands rare immunology portfolio of Italian drugmaker.
Italian pharmaceutical company Chiesi has agreed to acquire US-listed KalVista Pharmaceuticals for approximately $1.9 billion, its largest acquisition to date, to expand its rare immunology portfolio.
What happened
Italian pharmaceutical company Chiesi has agreed to acquire US-listed KalVista Pharmaceuticals for approximately $1.9 billion, its largest acquisition to date, to expand its rare immunology portfolio.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Oil prices jump 5% as markets react to concerns over a potential prolonged blockade of the Strait of Hormuz.
Oil prices rose by 5% amid market concerns regarding a potential prolonged blockade of the Strait of Hormuz.
Yum! Brands beats Q1 estimates with adjusted EPS of $1.50 vs $1.38 expected. KFC operating profit: $383M, margin 43.6%.
Yum! Brands reported Q1 adjusted EPS of $1.50, surpassing the estimate of $1.38. KFC operating profit reached $383 million with an operating margin of 43.6%.
U.S. gas prices hit fresh record of $4.23 per gallon, AAA reports, amid war with Iran.
U.S. gas prices have reached a new record since the start of the war with Iran, averaging $4.23 per gallon nationwide, according to AAA.
China Southern Airlines and a subsidiary agree to purchase Airbus aircraft in a deal valued at $21.4 billion.
China Southern Airlines and a subsidiary have agreed to purchase Airbus aircraft valued at $21.4 billion.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.